Humanistic Burden of Huntington Disease
Evidence From the Huntington Disease Burden of Illness Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 23, 2021
- Accepted September 13, 2022
- First Published October 12, 2022.
Article Versions
- Previous version (October 12, 2022 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Idaira Rodriguez Santana, PhD,
- Samuel Frank, MD,
- Maria Doherty, MSc,
- Rosa Willock, MSc,
- Jamie Hamilton, PhD,
- Hayley Hubberstey, PhD,
- Cath Stanley,
- Louise Vetter, BA,
- Michaela Winkelmann,
- Ricardo E. Dolmetsch, PhD,
- Nanxin Li, PhD,
- Sarah Ratsch, PhD and
- Talaha M. Ali, MD
- Idaira Rodriguez Santana, PhD,
None
NONE
None
NONE
NONE
NONE
HCD Economics, Senior Health Economist, 2.5 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Samuel Frank, MD,
I serve as the Chair of the DSMB for KINECT-HD, a Huntington Study Group study funded by Neurocrine biosciences.
NONE
None
Associate Editor of Journal of Huntington Disease
NONE
NONE
NONE
Amylyx Therapeutics, Novartis, Sage Therapeutics, uniQure
NONE
NONE
NONE
Roche/Genentech, Huntington Study Group/Vaccinex, Huntington Study Group/Prilenia, Sage Therapeutics, Triplet Therapeutics, uniQure
NONE
Huntington Study Group
CHDI Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Maria Doherty, MSc,
None
NONE
None
NONE
NONE
NONE
(1) Janssen Sciences Ireland, Senior Health Economics Market Access & Reimbursement Associate, 2022 (Note: current role, commenced May 2022)(2) HCD Economics, Health Economist, 2021-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Rosa Willock, MSc,
None
NONE
None
NONE
NONE
NONE
Employed by HCD Economics - contracted to complete this work. 1) Senior Real World Evidence Manager, 1 year
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Jamie Hamilton, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hayley Hubberstey, PhD,
None
NONE
None
NONE
NONE
NONE
COUCH Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Cath Stanley,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Louise Vetter, BA,
None
NONE
None
NONE
NONE
NONE
Huntington's Disease Society of America, Inc; President & CEO, 13 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Michaela Winkelmann,
Patient Advocate/Consultant at (Scientific) Advisory Boards for  Roche (02/2018; 02/2019; 06/2020) – unentgeltlich  Roche (10/2019 – 2mal; 03/2020; 11/2020) –> Empfänger: DHH  Wave Life Sciences (09/2018; 02/2019) - unentgeltlich  Azevan Pharmaceuticals (12/2019) - unentgeltlich  CHDI Foundation (08/2020) - unentgeltlich  PTC Therapeutics (11/2021) -> Empfänger: DHH  Novartis (03/2022) -> Empfänger: DHH  Roche (04/2022) – unentgeltlich  Novartis (geplant 07/2022) -> Empfänger: DHH
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Ricardo E. Dolmetsch, PhD,
None
NONE
None
NONE
NONE
NONE
uniQure Inc. President of R&D, 2020-
Tempero Bio
NONE
NONE
NONE
uniQure Inc.
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nanxin Li, PhD,
None
NONE
None
NONE
NONE
NONE
Former employee of uniQure, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
Former employee of uniQure holding stock or stock options, 2019-2022
NONE
NONE
- Sarah Ratsch, PhD and
None
NONE
None
NONE
NONE
NONE
(1) uniQure Inc., Sr. Director, 2 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
(1) uniQure NV
NONE
NONE
NONE
NONE
NONE
- Talaha M. Ali, MD
None
NONE
None
NONE
NONE
NONE
uniQure, Senior Director Global Medical Affairs, 2 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- HCD Economics (IRS, MD, RW); Harvard Medical School/Beth Israel Deaconess Medical Center (SF); CHDI Foundation (JH); Huntington's Disease Youth Organization (HDYO) (HH); Huntington's Disease Association (CS); Huntington's Disease Society of America (LV); Deutsche Huntington-Hilfe e.V (MW); and UniQure (RED, NL, SR, TMA), Inc, Lexington, MA.
- Correspondence
Dr. Rodriguez Santana idaira.rodriguez{at}primeglobalpeople.com
Article usage
The Nerve!: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Related Articles
- No related articles found.